Clinician-Guided Care
Every treatment plan is developed and monitored by licensed medical professionals to ensure safety, accuracy, and proper dosing.
+
+
.7★
Less Common but Reported Side Effects:
Serious but Rare Side Effects:
These medications act on two natural hormones that help regulate appetite and support healthy metabolic function. They are prescribed when clinically appropriate to improve consistency and control over eating habits.
They slow digestion and enhance the body’s hormonal response to food, helping promote steadier energy and improved appetite regulation throughout the day.
Invigor Medical provides compounded GLP-1 + GIP treatments when legally permissible and medically appropriate. Compounded medications are not FDA-approved and do not undergo FDA premarket review.
No. All evaluations, prescriptions, and follow-ups are managed through secure telehealth visits with licensed clinicians.
Most patients begin noticing changes in appetite or energy within several weeks, though response times vary by individual and dosage.
The most common side effects include nausea, constipation, diarrhea, fatigue, and mild stomach discomfort. Serious side effects such as pancreatitis or gallbladder issues are rare but require immediate medical attention.
These medications are not recommended for people with a history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pancreatitis, or severe gastrointestinal disease.
Your care team provides continuous clinical oversight, reviewing progress, and side effects to ensure safe and effective management over time.
Important Medication Info:
FDA-approved medications such as Mounjaro® and Zepbound™ are proprietary to Eli Lilly and Company™, while Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™. This website is not affiliated with, endorsed by, or associated with these companies or their products.
Invigor Medical does not supply FDA-approved branded medications. Instead, compounded GLP-1 + GIP alternatives may be prescribed when clinically appropriate and legally permissible. These compounded medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available options are unsuitable for an individual’s medical needs, but they have not been evaluated by the FDA to confirm safety or efficacy for any specific use.
Important Medication Info:
FDA-approved medications such as Mounjaro® and Zepbound™ are proprietary to Eli Lilly and Company™, while Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™. This website is not affiliated with, endorsed by, or associated with these companies or their products.
Invigor Medical does not supply FDA-approved branded medications. Instead, compounded GLP-1 + GIP alternatives may be prescribed when clinically appropriate and legally permissible. These compounded medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.
Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available options are unsuitable for an individual’s medical needs, but they have not been evaluated by the FDA to confirm safety or efficacy for any specific use.
Important Safety Information for GLP-1 + GIP Treatments
Compounded medications are legally prescribed under federal law but are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The GLP-1 + GIP treatment available through Invigor Medical is prescribed following an individualized medical evaluation by a licensed clinician.
WARNING: Risk of Thyroid C-Cell Tumors
In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether these effects occur in humans. Inform your healthcare provider if you experience neck swelling, hoarseness, difficulty swallowing, or shortness of breath. GLP-1 + GIP treatments should not be used by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use GLP-1 + GIP treatments if:
Warnings and Precautions:
Pregnancy and Reproductive Health:
GLP-1 + GIP medications may cause harm to a fetus and should not be used during pregnancy or by individuals planning to become pregnant. Discontinue at least two months before a planned pregnancy.
Common Side Effects:
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, fatigue, and headache are the most commonly reported side effects.
Drug Interactions:
GLP-1 + GIP treatments may slow gastric emptying and alter the absorption of oral medications. Consult your healthcare provider for guidance on timing and dosage adjustments.